Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming dysfunctional myeloid immune cells to revolutionize the management of a broad range of mitochondrial and immune mediated CNS and non-CNS indications and to significantly improve the lives of millions of patients. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapies work by restoring normal mitochondrial biogenesis, cell homeostasis and function, effectively “switching” microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism. For more information, visit www.tranquis.com.
Location: United States, California, Redwood City
Employees: 11-50
Total raised: $30M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | MBC BioLab... | mbcbiolabs... |
| - | Vivo Capit... | vivocapita... |
| - | SR One | srone.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2020 | Series A | $30M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.07.2020 | Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases | - |
| 09.07.2020 | Tranquis Therapeutics Receives $30M Series A | SAN MATEO, CA, Tranquis Therapeutics, a private immuno-neurology company, launched today with $30 million in Series A funding. >> Click here for more funding data on Tranquis Therapeutics >> To export Tranquis Therapeutics f... |
| 09.07.2020 | Tranquis Therapeutics Raises $30M in Series A Funding | Tranquis Therapeutics, a San Mateo, Calif.-based private immuno-neurology company, raised $30m in Series A funding. The round was co-led by Remiges Ventures and SR One, with participation from Vivo Capital, Hillsborough Venture, Correlation... |